Elite in Lung Cancer

Lizza E. Hendriks

Maastricht, LI, NL 
Clinical Trials:Currently Recruiting for 1 Trial
Elite in Lung Cancer
Maastricht, LI, NL 
OverviewLocationsClinical Research

Overview

Lizza Hendriks practices in Maastricht, Netherlands. Ms. Hendriks is rated as an Elite expert by MediFind in the treatment of Lung Cancer. Her top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Brain Tumor, and Small Cell Lung Cancer (SCLC).

Her clinical research consists of co-authoring 75 peer reviewed articles and participating in 3 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 61 articles and participated in 2 clinical trials in the study of Lung Cancer.

Gender
Female

Locations

Maastricht, LI, Netherlands
Other Locations
Nijmegen, GE, Netherlands
Heerlen, LI, Netherlands

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

3 Clinical Trials

SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
SPECTA: Screening Cancer Patients for Efficient Clinical Trial Access
Enrollment Status: Recruiting
Publish Date: May 01, 2025
Intervention Type: Genetic
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
A Phase II, Two-arm Study to Investigate Tepotinib Combined With Osimertinib in MET Amplified, Advanced or Metastatic NSCLC Harboring Activating EGFR Mutations and Having Acquired Resistance to Prior Osimertinib Therapy (INSIGHT 2)
Enrollment Status: Active_not_recruiting
Publish Date: December 12, 2025
Intervention Type: Drug
Study Drugs: Tepotinib, Osimertinib
Study Phase: Phase 2
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Activity of Lorlatinib Based on ALK Resistance Mutations on Blood in ALK Positive NSCLC Patients Previously Treated With 2nd Generation ALK Inhibitor
Enrollment Status: Active_not_recruiting
Publish Date: November 05, 2024
Intervention Type: Drug
Study Drug: Lorlatinib
Study Phase: Phase 2
View 2 Less Clinical Trial

75 Total Publications

Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC: Editorial on: The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.
Improved survival and rising incidence: insights from the largest retrospective study on leptomeningeal metastases in patients with NSCLC: Editorial on: The evolving landscape of leptomeningeal metastases from NSCLC: an international, contemporary, multicenter cohort study.
Journal: Annals of oncology : official journal of the European Society for Medical Oncology
Published: October 07, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Ms. Hendriks's expertise for a condition
ConditionClose
    View All 10 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile